Questcor regains some ground after Acthar hit but coverage concerns linger
This article was originally published in Scrip
On 20 September, Questcor Pharmaceuticals' stock recovered some of the value lost the previous day when the per-share price was cut almost in half after reports that US health insurance company Aetna would cover only one of the 19 approved indications for HP Acthar gel (repository corticotropin injection) (scripintelligence.com, 20 September 2012).
You may also be interested in...
Company anticipates steady sales of its blockbuster treatment for infantile spasms and other severe conditions for many years, despite agreement to out-license a potential competitor as part of settlement with US trade commission. Settlement resolving investigation into earlier Questcor acquisition also includes $100m fine.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.